IMNMHealthcare · BiotechnologyThe 16 Wall Street analysts covering Immunome, Inc. hold a median 12-month price target of $36 — +109.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 13 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Immunome, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (88): The shares have been drifting up relative to others.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IMNM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +109.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Stifel | Initiates | Hold | $24 |
| 21 Sept 2026 | Alliance Global Partners | Initiates | Buy | — |
| 21 Sept 2026 | Alliance Global Partners | Initiates | Buy | $32 |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $40 |
| 12 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 12 Aug 2026 | Truist Securities | Maintains | Buy | $37 → $38 |
| 12 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 12 Aug 2026 | Wedbush | Maintains | Outperform | $31 → $35 |
| 21 July 2026 | Wedbush | Reiterates | Outperform | — |
| 21 July 2026 | Wedbush | Reiterates | Outperform | $31 |
| 12 June 2026 | Wedbush | Reiterates | Outperform | $31 |
| 12 June 2026 | Wedbush | Reiterates | Outperform | — |
| 28 May 2026 | Barclays | Initiates | Overweight | — |
| 28 May 2026 | Truist Securities | Maintains | Buy | — |
| 15 May 2026 | Leerink Partners | Maintains | Outperform | — |
| 13 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 4 Mar 2026 | Stephens & Co. | Maintains | Overweight | — |
| 12 Feb 2026 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMNM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Immunome, Inc. returned +22.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 2% of US stocks
Cheaper than 23% of US stocks
Cheaper than 82% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 18% of US stocks
Higher than 11% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Immunome, Inc. has a market value of $2.3B and an enterprise value of $1.7B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$254.3M.
Free cash flow in the twelve months to 30 June 2026: −$228.1M.
Trailing P/E: −7.9×; forward P/E: −7.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Immunome, Inc. employs 247 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Immunome, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China on CNBC’s “Closing Bell Overtime.” The headline says large biopharma companies are looking at Chinese assets.
Why it matters — The discussion concerns broader biotech activity and does not mention Immunome specifically.
Immunome announced that its Compensation Committee granted inducement awards on October 1, 2026, consisting of stock options to purchase 120,900 shares and 7,200 restricted stock units.
Why it matters — The grants are relevant to IMNM watchers because they involve equity-based compensation and potential share dilution.
Immunome, Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) designed to treat advanced solid tumors. The company is a clinical-stage targeted oncology firm developing first-in-class and best-in-class cancer therapies.
Why it matters — This regulatory clearance advances IM-1340 toward clinical development, marking a key milestone for Immunome's pipeline of potential first-in-class cancer therapies.
Immunome announced that on September 1, 2026, its Compensation Committee granted inducement awards of non-statutory stock options to purchase a total of 86,500 shares of common stock to four new employees under Nasdaq Listing Rule 5635(c)(4). The grants are intended to incentivize the newly hired personnel.
Why it matters — The inducement grants signal ongoing hiring as Immunome builds out its team for its targeted cancer therapy pipeline, and the option awards will add to the company's potential share dilution.
Immunome, Inc., a clinical-stage targeted oncology company, announced that its management will present at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET. The presentation will be accessible via a live audio webcast on the Investor Relations section of the company's website.
Why it matters — Immunome watchers would be interested because the presentation offers an opportunity to hear directly from company management about its targeted cancer therapies at a prominent investment conference.
The 16 Wall Street analysts covering Immunome, Inc. have a median 12-month price target of $36, with estimates ranging from $24 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Immunome, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunome, Inc. 31 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Oct 2026, Immunome, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +109.3% from the last close, and Ticker Nerd's factor model ranks Immunome, Inc. 31 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Immunome, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $40 over the next 12 months.
Immunome, Inc. returned +22.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies.
The most recent item we track (CNBC Television, 6 Oct 2026): "Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter". Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China on CNBC’s “Closing Bell Overtime.” The headline says large biopharma companies are looking at Chinese assets.
Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s work centers on antibody-drug conjugates and other oncology-focused modalities designed to identify and attack specific disease targets while limiting effects on healthy tissue. Its current portfolio includes late-stage and early-stage programs such as varegacestat for desmoid tumors, IM-1021, and additional investigational assets in radiotherapy and solid-tumor antibody-drug conjugates. Immunome also uses proprietary antibody discovery capabilities to support the identification of novel therapeutic candidates and targets. Based in Bothell, Washington, Immunome operates as a research-driven drug development company serving the oncology market through a pipeline of clinical and preclinical assets.
CEO Dr. Clay B. Siegall Ph.D. · 247 employees · United States · https://immunome.com
